DiFusion Technologies announced issuance of US Patent No. 12,178,936 B2, Medical Implants and Methods of Manufacture. The new patent is encompasses four methods to manufacture ZFUZE, a proprietary therapeutic, anti-inflammatory, osseoconductive, load bearing biomaterial for orthopedic implants.
ZFUZE is reported to be the first FDA-cleared advanced biomaterial for spinal implants that is proven to create a highly favorable cellular and immunologic response post-surgery. Results from a 75-patient retrospective study indicate that ZFUZE posted a dominant 93.4% lumbar spinal fusion rate at 6 months, while similar competitive studies demonstrate average lumbar fusion rates of 68% at 12 months.
DiFusion Technologies announced issuance of US Patent No. 12,178,936 B2, Medical Implants and Methods of Manufacture. The new patent is encompasses four methods to manufacture ZFUZE, a proprietary therapeutic, anti-inflammatory, osseoconductive, load bearing biomaterial for orthopedic implants.
ZFUZE is reported to be the first FDA-cleared...
DiFusion Technologies announced issuance of US Patent No. 12,178,936 B2, Medical Implants and Methods of Manufacture. The new patent is encompasses four methods to manufacture ZFUZE, a proprietary therapeutic, anti-inflammatory, osseoconductive, load bearing biomaterial for orthopedic implants.
ZFUZE is reported to be the first FDA-cleared advanced biomaterial for spinal implants that is proven to create a highly favorable cellular and immunologic response post-surgery. Results from a 75-patient retrospective study indicate that ZFUZE posted a dominant 93.4% lumbar spinal fusion rate at 6 months, while similar competitive studies demonstrate average lumbar fusion rates of 68% at 12 months.
Copy to clipboard 
